IP Verse

Medical Use Of A Dpp-4 Inhibitor - EP3110449

The patent EP3110449 was granted to Boehringer Ingelheim on Jun 28, 2023. The application was originally filed on Feb 27, 2015 under application number EP15707338A. The patent is currently recorded with a legal status of "Revoked".

EP3110449

BOEHRINGER INGELHEIM
Application Number
EP15707338A
Filing Date
Feb 27, 2015
Status
Revoked
Jan 10, 2025
Grant Date
Jun 28, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 28, 2024ELKINGTON AND FIFEADMISSIBLE
POLPHARMAMar 26, 2024HAMM & WITTKOPPADMISSIBLE
WUESTHOFF & WUESTHOFFMar 26, 2024SONNENHAUSERADMISSIBLE
TEVA PHARMACEUTICALSMar 21, 2024VON KAUFFMANNADMISSIBLE
SANDOZMar 13, 2024ELKINGTON AND FIFEADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONEP2308878
EXAMINATIONUS2012121530
OPPOSITIONEP3110449
OPPOSITIONUS2012121530
OPPOSITIONWO2004018468
OPPOSITIONWO2005049022
OPPOSITIONWO2007128761
OPPOSITIONWO2010092124
OPPOSITIONWO2012065993
OPPOSITIONWO2015128453

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Center for Drug Evaluation and Research", U.S. Department of Health and Human Services, (20100908), no. 201280Orig1s000, pages 1 - 140, XP093181699-
OPPOSITION- Anonymous, "COMMISSION IMPLEMENTING DECISION of 24.8.2011 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Trajenta - linagliptin", a medicinal product for human use", COMMISSION IMPLEMENTING DECISION, European Commission, (20110824), pages 1 - 4, COMMISSION IMPLEMENTING DECISION , URL: https://ec.europa.eu/health/documents/community-register/2011/20110824116811/dec_116811_en.pdf, XP093177183-
OPPOSITION- Anonymous, "Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus (Diast Dysfkt)", ClinicalTrials.gov ID NCT01888796, (20170412), ClinicalTrials.gov ID NCT01888796, URL: https://clinicaltrials.gov/study/NCT01888796, XP093180319-
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO DRUG INFORMATION, GENEVA, CH, CH , (20080101), vol. 22, no. 8, ISSN 1010-9609, pages 121 - 174, XP093177179-
OPPOSITION- CONNELLY ET AL, "Dipeptidyl pertidase 4 inhibition improves left ventricular finction in chronic kidney disease", CLIN. INVEST. MED, (20140501), vol. 37, no. 3, pages E172 - E185, XP002738992-
OPPOSITION- Ema, "Trajenta®", EMA Summary of Product Characteristics, (20230109), pages 1 - 31, EMA Summary of Product Characteristics, URL: https://www.ema.europa.eu/en/documents/product-information/trajenta-epar-product-information_en.pdf, XP093180323-
OPPOSITION- Rwth Aachen University, "NCT01888796 Effect of Linagliptin Therapy on Myocardial Diastolic Function in Patients With Type 2 Diabetes Mellitus", ClinicalTrials.gov, NLM, (20131028), pages 1 - 10, ClinicalTrials.gov, URL: https://www.clinicaltrials.gov/study/NCT01888796?cond=NCT01888796&rank=1&tab=history&a=3#version-content-panel, XP093177188-
OPPOSITION- Burlew Brad S, Weber Karl T., "Cardiac Fibrosis as a Cause of Diastolic Dysfunction", HERZ., URBAN UND VOGEL, MUENCHEN., DE, DE , (20020301), vol. 27, no. 2, doi:10.1007/s00059-002-2354-y, ISSN 0340-9937, pages 92 - 98, XP093176877
OPPOSITION- Upshaw Jenica, Kiernan Michael S., "Preoperative Cardiac Risk Assessment for Noncardiac Surgery in Patients with Heart Failure", CURRENT HEART FAILURE REPORTS, CURRENT SCIENCE INC., PHILADELPHIA, PA,, US, US , (20130601), vol. 10, no. 2, doi:10.1007/s11897-013-0136-x, ISSN 1546-9530, pages 147 - 156, XP093182311
OPPOSITION- Oktay A. Afşin, Rich Jonathan D., Shah Sanjiv J., "The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction", CURRENT HEART FAILURE REPORTS, CURRENT SCIENCE INC., PHILADELPHIA, PA,, US, US , (20131201), vol. 10, no. 4, doi:10.1007/s11897-013-0155-7, ISSN 1546-9530, pages 401 - 410, XP093182305
OPPOSITION- Ronald M. Witteles, Khun Visith Keu, Andrew Quon, Homa Tavana, Michael B. Fowler, "Dipeptidyl Peptidase 4 Inhibition Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy", Journal of Cardiac Failure, Churchill Livingstone, (20121001), vol. 18, no. 10, doi:10.1016/j.cardfail.2012.07.009, ISSN 10719164, pages 804 - 809, XP055186174
OPPOSITION- Hocher Berthold; Sharkovska Yuliya; Mark Michael; Klein Thomas; Pfab Thiemo, "The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats", International Journal of Cardiology, AMSTERDAM, NL , (20120102), vol. 167, no. 1, doi:10.1016/j.ijcard.2011.12.007, ISSN 0167-5273, pages 87 - 93, XP028556713
OPPOSITION- Akshay S. Desai, "Heart Failure With Preserved Ejection Fraction", Journal of the American College of Cardiology, Elsevier, (20130701), vol. 62, no. 4, doi:10.1016/j.jacc.2013.03.075, ISSN 07351097, pages 272 - 274, XP055098357
OPPOSITION- Yancy Clyde W.; Jessup Mariell; Bozkurt Biykem; Butler Javed; Casey Donald E.; Drazner Mark H.; Fonarow Gregg C.; Geraci Stephen A.; Horwich Tamara; Januzzi James L.; Johnson Maryl R.; Kasper Edward K.; Levy Wayne C.; Masoudi Frederick A.; McBride Patrick E.; McMurray John J.V.; Mitchell Judith E.; Peterson Pamela N.; Riegel Barbara; Sam Flora; Stevenson Lynne W.; Tang W.H. Wilson; Tsai Emily J.; Wilkoff Bruce L., "2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines ", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130605), vol. 62, no. 16, doi:10.1016/j.jacc.2013.05.019, ISSN 0735-1097, XP028733857
OPPOSITION- Advani Andrew, Bugyei-Twum Antoinette, Connelly Kim A., "Cardiovascular Effects of Incretins in Diabetes", Canadian Journal of Diabetes, (20131001), vol. 37, no. 5, doi:10.1016/j.jcjd.2013.06.010, ISSN 1499-2671, pages 309 - 314, XP093177190
OPPOSITION- Dimitrios M. Konstantinou, Yiannis S. Chatzizisis, George D. Giannoglou, "Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction", Pharmacology & Therapeutics, Pergamon, (20131101), vol. 140, no. 2, doi:10.1016/j.pharmthera.2013.05.012, ISSN 01637258, pages 156 - 166, XP055186154
OPPOSITION- Shiraki A, Oyama J, Shimizu T, Node N, "The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice", ESC Congress, GB , (20221003), vol. 43, no. Supplement_2, doi:10.1093/eurheartj/ehac544.2682, ISSN 0195-668X, pages 2682 - 2682, XP093142569
OPPOSITION- Connelly Kim Alexander, Zhang Yanling; Advani Andrew; Advani Suzanne L.; Thai Kerri; Yuen Darren A.; Gilbert Richard E., "DPP‐4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes", Cardiovascular Therapeutics, (20131001), vol. 31, no. 5, doi:10.1111/1755-5922.12005, ISSN 1755-5914, pages 259 - 267, XP093176879
OPPOSITION- Daniel Burkhoff, "Assessment of systolic and diastolic ventricular properties via pressure volume analysis: a guide for clinical, translational, and basic researchers", Am. J. Physiol. Heart Circ. Physiol , (2005), vol. 289, doi:10.1152/ajpheart.00138.2005, XP055265456
OPPOSITION- Yancy Clyde W, Yancy Clyde W, Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey, Drazner Mark H, Fonarow Gregg C, Geraci Stephen A, Horwich Tamara, Januzzi James L, Johnson Maryl R, Kasper Edward K, Levy Wayne C, Masoudi Frederick A, Mcbride Patrick E, Mcmurray John, Mitchell Judith E, Peterson Pamela N, Riegel Barbara, Sam Flora, Stevenson Lynne W, Tang W, Tsai Emily J, Wilkoff Bruce L, "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines", Circulation, American Heart Association, US, US , (20131015), vol. 62, no. 16, doi:10.1161/CIR.0b013e31829e8776, ISSN 0009-7322, pages e147 - e239, XP093180312
OPPOSITION- Dos Santos Leonardo, Salles Thiago A., Arruda-Junior Daniel F., Campos Luciene C.G., Pereira Alexandre C., Barreto Ana Luiza T., Antonio Ednei L., Mansur Alfredo J., Tucci Paulo J.F., Krieger José E., Girardi Adriana C.C., "Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure", Circulation. Heart Failure (Print), Lippincott Williams & Wilkins, US, US , (20130901), vol. 6, no. 5, doi:10.1161/CIRCHEARTFAILURE.112.000057, ISSN 1941-3289, pages 1029 - 1038, XP093177547
OPPOSITION- Shigeta Toshimasa, Aoyama Morihiko; Bando Yasuko K; Monji Akio; Mitsui Toko; Takatsu Miwa; Cheng Xiang-Wu; Okumura Takahiro; Hirashiki Akihiro; Kohzo Nagata; Murohara Toyoaki, "Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions", Circulation, (20120101), vol. 126, doi:10.1161/CIRCULATIONAHA.112.096479/-/DC1., pages 1838 - 1851, XP093176880
OPPOSITION- Toshimasa Shigeta, "Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions", Circulation, (2012), vol. 126, doi:10.1161/CIRCULATIONAHA.112.096479/-/DC1, XP093176880
OPPOSITION- Darren K. McGuire, "Linagliptin Effects on Heart Failure and Related Outcome in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA", Circulation, (201901), vol. 139, doi:10.1161/CIRCULATIONAHA.118.038352, XP093142549
OPPOSITION- Jose Tessey, Inzucchi Silvio E, "Cardiovascular effects of the DPP-4 inhibitors", Diabetes and Vascular Disease Research, GB , (20120401), vol. 9, no. 2, doi:10.1177/1479164111436236, ISSN 1479-1641, pages 109 - 116, XP093181714
OPPOSITION- Mcgill Janet B., "Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials", Therapeutic advances in endocrinology and metabolism, Sage Publications Ltd, GB, GB , (20120801), vol. 3, no. 4, doi:10.1177/2042018812449406, ISSN 2042-0188, pages 113 - 124, XP093180308
OPPOSITION- Baptist Gallwitz, "Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors", Therapeutic advances in endocrinology and metabolism, GB , (20130601), vol. 4, no. 3, doi:10.1177/2042018813486165, ISSN 2042-0188, pages 95 - 105, XP055397362
OPPOSITION- Johansen Odd, Neubacher Dietmar, Von Eynatten Maximilian, Patel Sanjay, Woerle Hans-Juergen, "Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme", Cardiovasc Diabetology, GB , (20120101), vol. 11, no. 1, doi:10.1186/1475-2840-11-3, ISSN 1475-2840, pages 1 - 10, XP093150014
OPPOSITION- Erika Paniago Guedes;Alexandre Hohl;Thais Gomes de Melo;Felipe Lauand, "Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment", Diabetology & Metabolic Syndrome, BioMed Central Ltd, London, UK, London, UK , (20130522), vol. 5, no. 1, doi:10.1186/1758-5996-5-25, ISSN 1758-5996, page 25, XP021151721
OPPOSITION- Aroor Annayya R., Sowers James R., Bender Shawn B., Nistala Ravi, Garro Mona, Mugerfeld Irina, Hayden Melvin R., Johnson Megan S., Salam Muhammad, Whaley-Connell Adam, Demarco Vincent G., "Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats", Endocrinology, The Endocrine Society, US, US , (20130701), vol. 154, no. 7, doi:10.1210/en.2013-1096, ISSN 0013-7227, pages 2501 - 2513, XP093180309
OPPOSITION- Aroor Annayya R., Sowers James R., Bender Shawn B., Nistala Ravi, Garro Mona, Mugerfeld Irina, Hayden Melvin R., Johnson Megan S., Salam Muhammad, Whaley-Connell Adam, Demarco Vincent G., "Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats", Endocrinology, US , (20130701), vol. 154, no. 7, doi:10.1210/en.2013-1096, ISSN 0013-7227, pages 2501 - 2513, XP093180309
OPPOSITION- Lyubov Chaykovska, "Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy", Plos One, (201111), vol. 6, doi:10.1371/journal.pone.0027861, XP055073329
OPPOSITION- Lyubov Chaykovska, Von Websky Karoline, Rahnenführer Jan, Alter Markus, Heiden Susi, Fuchs Holger, Runge Frank, Klein Thomas, Hocher Berthold, "Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy", PLoS ONE, (20111101), vol. 6, no. 11, doi:10.1371/journal.pone.0027861, pages 1 - 9, XP055073329
OPPOSITION- Lyubov Chaykovska; Von Websky Karoline; Rahnenführer Jan; Alter Markus; Heiden Susi; Fuchs Holger; Runge Frank; Klein Thomas; Hocher Berthold, "Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy", PLoS ONE, (20111101), vol. 6, no. 11, doi:10.1371/journal.pone.0027861, pages 1 - 9, XP055073329
OPPOSITION- Gallwitz Baptist, "Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes", Diabetes, Metabolic Syndrome and Obesity: targets and therapy, Dove Medical Press Ltd., GB, GB , (20130101), doi:10.2147/DMSO.S23166, ISSN 1178-7007, pages 1 - 9, XP093182300
OPPOSITION- J.B. McGill et al., "Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment", Diabetes Care, (2013), vol. 36, doi:10.2337/dc12-0706, XP055073250
OPPOSITION- J.B. McGill, "Long-Term Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes and Severe Renal Impairment", Diabetes Care, (20130101), vol. 36, doi:10.2337/dc12-0706, pages 237 - 244, XP055073250

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents